Immutep (ASX:IMM)
ASX announcement history & article coverage
Transparent by design.
Announcments by Immutep (ASX:IMM) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Immutep Outlines Focused Development Strategy for Efti
Immutep narrows efti strategy after TACTI-004 manufacturing analysis
Appendix 4E & 2026 Full Year Statutory Accounts
Immutep Corporate Presentation
Immutep Quarterly Activities Report and Appendix 4C
Immutep reports positive eftilagimod alfa trial results, discontinues TACTI-004 Phase III, and maintains strong cash position
Abstract Accepted for Presentation at ESMO Congress 2026
Fourth U.S. Patent Secured for Efti and PD-1 Combination
TACTI-004 Update & Positive Mature Data from INSIGHT-003
Immutep reports positive mature survival data in 1L NSCLC from INSIGHT-003; TACTI-004 trial discontinued with ongoing root cause analysis
Ceasing to be a substantial holder
Becoming a substantial holder
Ceasing to be a substantial holder
Becoming a substantial holder